FDA Advisors Said It Should Approve the Grail Multicancer Blood Test
Guardant Health Inc GH
$177.25
▲ +0.45%
(+$0.80)
Open
$178.50
Prev Close
$176.45
Day Range
$174.50 – $179.97
52W Range
$55.38 – $183.51
Market Cap
$23.79B
Beta
1.73
EPS (TTM)
$-3.50
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-04 |
| Shares Out. | 132,600,000 |
| Website | guardanthealth.com/ ↗ |
| Phone | 13025310855 |
| Employees | 2,506 |
| Revenue | $335.0M |
| Gross Profit | $219.0M |
| Net Income | -$120.1M |
| Free Cash Flow | -$240.7M |
| Total Assets | $1.91B |
| Total Liabilities | $2.14B |
| Equity | -$222.9M |
About Guardant Health Inc
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health Inc is a publicly traded company under the ticker symbol GH on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
35 analysts (2026-09-01)
📰 Latest News for GH
Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Cathie Wood Makes a Big AI Bet and Cuts Bitcoin Exposure
1 Unpopular Stock That Should Get More Attention and 2 We Question
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)